Contract Manufacturing Organization Remain Primary End User
Contract manufacturing organizations (CMO) are reinventing their strategies to align with the changing dynamics of pharmaceutical industry - cost reduction, and enhanced differentiation from peers. Prominent pharmaceutical companies highly rely on CMOs for manufacturing APIs as well as final formulations. Integration of CMOs into supply chain of pharmaceutical companies is becoming commonplace. CMOs are also pairing with other CMOs in a bid to offer combined services. This study further underlines that CMOs would generate 50% total return to shareholders through 2029.
Asia to Offer Second Wave of Growth
Driven by strong foothold of leading manufacturers and high adoption of non-steroidal anti-inflammatory drugs (NSAID), North America would remain the hub of investment opportunities in ibuprofen API market. However, Asia is expected to offer further opportunities of growth and profitability in the years ahead. Availability of cheap labor, and abundant raw materials needed to develop ibuprofen API are primarily responsible for market growth in the region.
Conducive regulatory environment to set up manufacturing facilities, and reduced taxation policies are also significantly attracting stakeholders. Furthermore, majority of the antibiotic drugs and anti-inflammatory drugs are manufactured in Asia, of which, about 80% are developed in China, and India.
Mergers & Acquisitions - Critical to Market Progress
Various pharmaceutical companies in the ibuprofen API market are focusing on mergers & acquisitions with CMOs to establish their proprietary pharmaceutical intermediate and small molecule API units to enhance the supply of raw materials and keep up with the pace of the manufacturing of the final formulation.
Over the recent past, the number of deals in pharma API industry has surged with the aim to address therapeutic, pipeline, and geographic expansion needs. Mergers & acquisitions thus play a big part in the growth tactics for majority of pharmaceutical companies in ibuprofen API market by saving time and costs.
How Growth will Unfold
Several pharmaceutical and biopharmaceutical companies are aggressively moving toward enhanced production capacity to boost their global presence. For instance, BASF SE is looking forth to increase its production capabilities in Germany and the US. By 2023, the company expects to witness an upsurge in its capacity by over 30%. Moving on, the World Health Organization (WHO) states that incidents of chronic diseases will surge by around 60% in 2020, accenting the need for ibuprofen API.
However, factors such as unstable supply of required components, and rise in raw material prices - Isobutyl Benzene - are likely to hamper the growth of ibuprofen API market. Manufacturers are confronting downward pricing pressure that leaves limited scope for innovation in manufacturing techniques. As such, the market is yet fully embrace tech-enabled transformations.
IBUPROFEN API MARKET TAXONOMY
The global ibuprofen API market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
End User
- Contract Manufacturing Organizations
- Pharmaceutical Companies
Region
- North America
- Europe
- Latin America
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports